Indication
Primary Peritoneal Cavity Cancer
9 clinical trials
13 products
7 drugs
Clinical trial
A Phase 1, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants With Solid TumorsStatus: Recruiting, Estimated PCD: 2026-12-01
Product
XMT-1660Clinical trial
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerStatus: Not yet recruiting, Estimated PCD: 2028-06-30
Product
FT536Product
FludarabineDrug
cyclophosphamideClinical trial
Phase IB-II, Open Label, Multicenter Feasibility Study of Pazopanib in Combination With Paclitaxel and Carboplatin in Patients With Platinum-Refractory/Resistant Ovarian, Fallopian Tube or Peritoneal CarcinomaStatus: Completed, Estimated PCD: 2019-05-15
Drug
carboplatinDrug
paclitaxelProduct
PazopanibClinical trial
A Phase I Dose Escalation Safety and Feasibility Study of WT1-Specific T Cells for the Treatment of Patients With Advanced Ovarian, Primary Peritoneal, and Fallopian Tube CarcinomasStatus: Completed, Estimated PCD: 2021-08-03
Product
filgrastimClinical trial
Phase I Trial of Intraperitoneal Administration of a) a CEA-Expressing Derivative, and b) a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian CancerStatus: Completed, Estimated PCD: 2012-08-01
Clinical trial
A Phase I Study Of NY-ESO-1b Peptide Plus Montanide ® ISA-51 In Patients With Ovarian, Primary Peritoneal, Or Fallopian Tube CancerStatus: Completed, Estimated PCD: 2006-05-09
Product
NY-ESO-1Clinical trial
A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction With Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal CancerStatus: , Estimated PCD: 2025-02-25
Product
MetforminDrug
placeboDrug
AN0025Clinical trial
Intraperitoneal FATE FT516 and Interleukin-2 (IL-2) With Intravenous Enoblituzumab in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerStatus: Completed, Estimated PCD: 2022-01-01
Product
IP FT516Drug
EnoblituzumabDrug
interleukin-2Clinical trial
A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Expansion Study of AVB-001, an Intraperitoneally Administered, Cell-Generated, Human IL-2 Immunotherapy in Patients With Platinum-Resistant, High-Grade, Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian TubeStatus: Terminated, Estimated PCD: 2024-04-01
Product
AVB-001